KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Receivables - Net (2016 - 2025)

Jazz Pharmaceuticals has reported Receivables - Net over the past 16 years, most recently at $830.7 million for Q4 2025.

  • Quarterly results put Receivables - Net at $830.7 million for Q4 2025, up 15.9% from a year ago — trailing twelve months through Dec 2025 was $830.7 million (up 15.9% YoY), and the annual figure for FY2025 was $830.7 million, up 15.9%.
  • Receivables - Net for Q4 2025 was $830.7 million at Jazz Pharmaceuticals, up from $764.4 million in the prior quarter.
  • Over the last five years, Receivables - Net for JAZZ hit a ceiling of $830.7 million in Q4 2025 and a floor of $414.0 million in Q1 2021.
  • Median Receivables - Net over the past 5 years was $639.7 million (2022), compared with a mean of $638.9 million.
  • Biggest five-year swings in Receivables - Net: soared 43.97% in 2021 and later dropped 7.65% in 2025.
  • Jazz Pharmaceuticals' Receivables - Net stood at $563.4 million in 2021, then increased by 15.64% to $651.5 million in 2022, then grew by 8.33% to $705.8 million in 2023, then rose by 1.55% to $716.8 million in 2024, then grew by 15.9% to $830.7 million in 2025.
  • The last three reported values for Receivables - Net were $830.7 million (Q4 2025), $764.4 million (Q3 2025), and $714.0 million (Q2 2025) per Business Quant data.